Shunmoogam Nelusha, Naidoo Poobalan, Chilton Robert
Sanofi, Midrand, South Africa.
Department of Medicine, Division of Cardiology and Interventional Cardiology, University of Texas Health Science Center at San Antonia, San Antonia, TX, USA.
Vasc Health Risk Manag. 2018 Jun 18;14:137-143. doi: 10.2147/VHRM.S165173. eCollection 2018.
Paraoxonase-1 (PON1) is a high-density lipoprotein-associated esterase and is speculated to play a role in several human diseases including diabetes mellitus and atherosclerosis. Low PON1 activity has been associated with increased risk of major cardiovascular events, therefore a variety of studies have been conducted to establish the cardioprotective properties and clinical relevance of PON1. The major aim of this review was to highlight the important studies and to subsequently assess if PON1 has clinical relevance. A review of the literature showed that there is currently insufficient data to suggest that PON1 has clinical relevance. It is our opinion that robust studies are required to clarify the clinical relevance of PON1.
对氧磷酶-1(PON1)是一种与高密度脂蛋白相关的酯酶,据推测在包括糖尿病和动脉粥样硬化在内的多种人类疾病中发挥作用。PON1活性降低与主要心血管事件风险增加有关,因此已经开展了各种研究来确定PON1的心脏保护特性和临床相关性。本综述的主要目的是突出重要研究,并随后评估PON1是否具有临床相关性。文献综述表明,目前尚无足够数据表明PON1具有临床相关性。我们认为需要开展有力的研究来阐明PON1的临床相关性。